CD19 and acute lymphoblastic leukemia: Indeed, CD19-TRAIL treatment was efficient in all tested PDX-samples in vivo and significantly prolonged the survival of PDX-animals irrespective of ALL cytogenetics (Supplementary Table S1; Figure 4C–F).